Program
pirfenidone
Also written as “Pirfenidone”, “Pirfenidone Modified-Release Tablets” and “Deupirfenidone”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Lung Injury · Lung Diseases, Interstitial · Pulmonary Fibrosis · COVID-19, led by 6 companies.
Drug pagePirfenidone: every studyMany companies study it; this page follows only the 29 they lead. All 102 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 120 open or running | phase 4since Nov 4, 2015 | Mar 24, 2004 | none ahead |
| GNI Groupits history only | 72 open or running | phase 3since Feb 26, 2019 | Nov 18, 2014 | Dec 30, 2026phase 3 · NCT07388680 |
| PureTech | 52 open or running | phase 3since Dec 8, 2025 | Jan 21, 2020 | Nov 2029phase 3 · NCT07284602 |
| Overseas Pharmaceuticalsits history only | 30 open or running | phase 1since Aug 22, 2024 | Aug 22, 2024 | none ahead |
| beijing-kawin-technology-share-holding-co-ltdits history only | 10 open or running | phase 2since Dec 30, 2011 | Dec 30, 2011 | none ahead |
| grupo-medifarma-s-a-de-c-vits history only | 10 open or running | phase 3since Jul 6, 2015 | Jul 6, 2015 | none ahead |
Also a collaborator on its studies: Clinipace Worldwide, Novotech (Australia) Pty, Shanghai Genomics and GNI-EPS Pharmaceuticals, Inc. (GNI Group).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of PureTech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 21, 2020First study: phase 2 study in LymphedemaFirst studyNCT04243837 · 50 enrolled · United States, Australia
- Dec 2, 2020Phase 2 study in COVID-19NCT04652518 · 185 enrolled · United States, Argentina, Brazil and more
- Apr 2, 2022Phase 2 study in Idiopathic Pulmonary FibrosisNCT05321420 · 240 enrolled · United States, Argentina, Chile and more
- Dec 8, 2025Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedNCT07284602 · 1,100 planned · United States, Canada
- Feb 19, 2026Phase 1 study in Pharmacokinetic AnalysisNCT07456800 · 116 enrolled · United States
Ahead
- Nov 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07284602
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 PureTech leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07456800Pharmacokinetic Analysis · United States | 1 | Completed | Jan 1, 2022 | 116 |
| NCT07284602Idiopathic Pulmonary Fibrosis · United States, Canada | 3 | Recruiting | Nov 2029 | 1,100 |
| NCT05321420Idiopathic Pulmonary Fibrosis · United States, Argentina, Chile and more | 2 | Active, not recruiting | Oct 15, 2024 | 240 |
| NCT04652518COVID-19 · United States, Argentina, Brazil and more | 2 | Terminated | Jun 28, 2022 | 185 |
| NCT04243837Lymphedema · United States, Australia | 2 | Terminated | Sep 9, 2022 | 50 |
How it is read
Names in the registry
- “Pirfenidone”, 26 entries
- “Pirfenidone Modified-Release Tablets”, 4 entries
- “Deupirfenidone”, 3 entries
- “pirfenidone capsule”, 2 entries
- “pirfenidone”, 2 entries
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 21 studies
- Lung Injury, 2 studies
- Lung Diseases, Interstitial, 2 studies
- Pulmonary Fibrosis, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.